Targeting TPO/MPL Signaling to Mitigate JAK2V617F-driven Cardiac Microvascular Disease

This study demonstrates that JAK2V617F-mutant hematopoiesis drives cardiac microvascular disease and endocardial injury through upregulated TPO/MPL signaling in endocardial endothelial cells, a pathological process that can be effectively mitigated by neutralizing MPL.

The Gist

The Big Picture: A "Bad Neighbor" Problem in the Heart

Imagine your heart is a bustling city. The blood cells are the delivery trucks and workers moving through the streets, while the heart's inner lining (the endocardium) is the smooth, protective pavement that keeps the streets running smoothly.

Usually, these workers and the pavement get along fine. But in this study, scientists discovered a specific type of "mutant worker" (caused by a genetic glitch called JAK2V617F) that causes trouble even if the pavement itself is perfectly healthy.

This mutation is found in many people with blood disorders or even in healthy older adults. These people have a much higher risk of heart disease, but doctors didn't fully understand why until now. This paper explains how these mutant blood cells attack the heart's "pavement," leading to clogged tiny streets and heart failure, and how a new treatment might fix it.

---

1. The Setup: The "Bad Neighbor" Moves In

The researchers created a special group of mice. They took healthy mice and gave them bone marrow from mice with the JAK2V617F mutation.

• The Result: The mice had healthy heart walls (the "pavement"), but their blood was full of these "mutant workers."
• The Observation: Even without any other health issues, these mice started developing problems. Their heart chambers got slightly bigger, and the tiny blood vessels inside the heart began to narrow. It was like the delivery trucks were so aggressive they started bumping into the walls, causing the streets to get clogged.

2. The Stress Test: Adding "Junk Food" to the Mix

To see what happens when things get worse, the researchers fed these mice a High-Fat/High-Cholesterol diet (think of it as a diet of greasy burgers and sugary drinks).

• The Disaster: The combination of the "mutant workers" and the "junk food" was a recipe for disaster.
  • The tiny streets (coronary arterioles) became severely narrowed (stenosis).
  • The area around the streets became covered in scar tissue (fibrosis), like weeds choking a garden.
  • The Critical Damage: The inner "pavement" (the endocardium) started to crack and peel off.
• The Twist: Surprisingly, the main pumping power of the heart (the ejection fraction) stayed mostly normal for a while. This mimics a real human condition called Heart Failure with Preserved Ejection Fraction (HFpEF), where the heart is stiff and clogged but still pumps with decent force.

3. The Detective Work: Finding the Target

The scientists used high-tech "microscopes" (single-cell RNA sequencing) to look at the heart cells one by one. They found that the damage wasn't happening everywhere equally.

• The Culprit: The damage was focused almost entirely on the Endocardial Cells (the cells lining the inside of the heart chambers).
• The Weapon: These specific cells had a unique "lock" on their surface called MPL. The mutant blood cells were sending out signals (via a key called TPO) that fit perfectly into this MPL lock, turning the cells into a chaotic, inflamed mess.
• The Analogy: Imagine the mutant blood cells are vandals throwing rocks. The Endocardial cells are the only ones wearing a specific "target vest" (MPL) that makes them the primary target. The other blood vessels in the heart didn't wear this vest, so they were mostly safe.

4. The Solution: The "Shield" (AMM2 Antibody)

The researchers tried a new treatment: an antibody called AMM2.

• How it works: Think of AMM2 as a shield or a plug. It covers the MPL "lock" on the heart cells, so the mutant blood cells can no longer send their damaging signals.
• The Result:
  • The Shield Worked: When they gave the mice the AMM2 shield, the heart damage stopped.
  • Healing: The cracked pavement (endocardium) was repaired. The scar tissue (fibrosis) disappeared. The tiny streets opened up again, and new healthy vessels grew.
  • Safety: Crucially, this shield did not stop the mutant blood cells from doing their job in the rest of the body (like making platelets). It only protected the heart.

5. Why This Matters for Humans

This study is a game-changer for two main reasons:

1. It explains a mystery: It tells us why people with this specific blood mutation get heart disease even if their arteries aren't blocked by plaque (atherosclerosis). It's a "microvascular" problem, like clogged tiny pipes rather than a blocked main highway.
2. It offers a new treatment: Instead of trying to fix the blood mutation (which is hard), we can protect the heart by blocking the MPL signal. This could lead to new drugs to prevent heart failure in people with this mutation, especially those who are also eating a poor diet or are under stress.

Summary Analogy

Imagine a city where the delivery trucks (blood cells) have gone crazy and are driving recklessly.

• Old Thinking: We thought the roads (arteries) were getting clogged with trash (plaque).
• New Discovery: The roads are fine, but the sidewalks (endocardium) are getting destroyed because the trucks keep hitting a specific button (MPL) on the sidewalk.
• The Fix: We put a protective cover over that button. The trucks can still drive, but they can't break the sidewalk anymore. The city (the heart) stays safe and functional.

In short: This paper finds a specific "weak spot" in the heart caused by bad blood cells and shows that we can plug that hole to prevent heart disease.

Technical Summary

1. Problem Statement

Individuals with JAK2V617F-mutant myeloproliferative neoplasms (MPNs) or clonal hematopoiesis of indeterminate potential (CHIP) face a significantly elevated risk of cardiovascular disease (CVD), including heart failure and thrombosis. While the mutation drives the expansion of mutant blood cells, the specific mechanisms by which these mutant hematopoietic cells induce vascular and cardiac dysfunction—particularly in the absence of overt epicardial coronary artery disease—remain incompletely understood. Previous models suggested that endothelial expression of the mutation was required for severe pathology, but the role of mutant blood cells acting on wild-type endothelium, especially under metabolic stress, was unclear. Furthermore, the specific cellular targets within the heart and the signaling pathways mediating this injury were not fully characterized.

2. Methodology

The study employed a multi-faceted approach combining in vivo murine models, in vitro assays, and advanced genomic techniques:

• Animal Models:
  • Chimeric Mice: Bone marrow transplantation was performed using JAK2V617F-mutant hematopoietic cells (from Tie2-cre+FF1+ donors) into wild-type (WT) recipients (CD45.1 background). This created mice with mutant blood cells but wild-type endothelium.
  • Dietary Challenge: Mice were subjected to a High-Fat/High-Cholesterol Diet (HFD) for 5 weeks to induce cardiometabolic stress, simulating a Western lifestyle.
  • Therapeutic Intervention: A subset of mutant mice received the anti-MPL neutralizing antibody (AMM2) (0.1 mg/kg IV every 10 days) to block TPO/MPL signaling.
• Phenotypic Assessment:
  • Echocardiography: Serial measurements of Left Ventricular (LV) ejection fraction (LVEF), volumes, and mass.
  • Histology: H&E and Masson's Trichrome staining to assess coronary arteriole stenosis (luminal radius-to-wall thickness ratio), perivascular fibrosis, and subendocardial collagen deposition.
  • Microvascular Density: In vivo labeling with anti-VE-cadherin antibodies followed by immunofluorescence imaging.
• Molecular & Genomic Analysis:
  • Single-Cell RNA Sequencing (scRNA-seq): Performed on cardiac non-cardiomyocyte cells to identify specific endothelial subpopulations (arterial, venous, capillary, and endocardial) and their transcriptomic responses.
  • Flow Cytometry & Immunohistochemistry (IHC): Used to map the expression of the MPL receptor across different cardiac endothelial layers.
  • In Vitro Co-culture: WT cardiac endothelial cells (ECs) were co-cultured with mutant blood mononuclear cells to assess angiogenic capacity (tube formation assays).

3. Key Contributions

• Identification of a Distinct Phenotype: The study establishes that JAK2V617F-mutant hematopoiesis alone is sufficient to drive cardiac microvascular disease characterized by coronary arteriole stenosis, perivascular fibrosis, and endocardial injury, even without epicardial atherosclerosis or myocardial infarction.
• Discovery of Endocardial Vulnerability: The authors identified endocardial endothelial cells (ECs) as the primary cellular target of mutant hematopoiesis under metabolic stress. Unlike arterial, venous, or capillary ECs, endocardial ECs showed the most profound transcriptomic dysregulation.
• Novel Localization of MPL: The paper provides the first evidence that the Thrombopoietin (TPO) receptor MPL is selectively and predominantly expressed in a subset of endocardial ECs in the murine heart, rather than being uniformly distributed across all vascular beds.
• Therapeutic Targeting: The study demonstrates that pharmacological blockade of the TPO/MPL axis using the neutralizing antibody AMM2 can rescue cardiac function and microvascular integrity without altering systemic hematopoiesis.

4. Key Results

• Pathology Induction:
  • Mice with JAK2V617F-mutant blood cells on a standard diet showed early signs of microvascular remodeling and inflammation.
  • Under HFD stress, these mice developed a distinct CVD phenotype: increased LV mass, reduced LVEF, coronary arteriole stenosis, and significant perivascular and subendocardial fibrosis.
  • Histology revealed endocardial disruption (irregular lining, cellular enlargement) in mutant mice, which was absent in controls.
• Transcriptomic Insights:
  • scRNA-seq revealed that endocardial ECs in mutant mice exhibited upregulation of inflammatory pathways (TNF-$\alpha$/NF-$\kappa$B, IFN-$\alpha$/$\gamma$), stress responses (p53, apoptosis, hypoxia), and Endothelial-to-Mesenchymal Transition (EndMT) signatures.
  • MPL Expression: IHC and flow cytometry confirmed MPL is highly expressed in endocardial ECs but largely absent in other cardiac EC types.
• Therapeutic Efficacy of AMM2:
  • Treatment with AMM2 in mutant mice on HFD restored endocardial integrity, significantly reduced perivascular and subendocardial fibrosis, and increased coronary microvascular density.
  • AMM2 treatment normalized LV volumes and preserved LVEF, effectively preventing the progression to heart failure.
  • Mechanism: AMM2 suppressed inflammatory and stress-response gene signatures specifically in endocardial ECs. Crucially, this cardioprotection occurred despite persistent systemic inflammation (elevated IL-6, TNF-$\alpha$, IL-1$\beta$) and without altering peripheral blood counts or bone marrow megakaryocytes, indicating a direct effect on the cardiac endothelium.

5. Significance

• Clinical Relevance: The findings offer a mechanistic explanation for the high rate of heart failure (particularly HFpEF) and microvascular dysfunction in patients with JAK2V617F-positive CHIP or MPNs, independent of traditional atherosclerosis.
• Novel Therapeutic Strategy: The study identifies TPO/MPL signaling in endocardial ECs as a druggable target. The use of an MPL-neutralizing antibody (AMM2) suggests a potential strategy to mitigate cardiovascular risk in this high-risk population without the hematologic toxicity associated with JAK inhibitors or the need to eliminate the mutant clone.
• Paradigm Shift: It challenges the notion that endothelial mutation is required for vascular injury, showing instead that mutant blood cells can drive severe cardiac pathology via paracrine signaling to specific, vulnerable endothelial subsets (endocardial ECs).
• Future Directions: This work provides a preclinical model for testing anti-inflammatory and anti-fibrotic therapies for clonal hematopoiesis-associated heart disease and highlights the critical role of the endocardium in cardiac homeostasis and repair.